Oncology

Breast Implants Linked to Increased Risk of Developing Breast ALCL

A new study found that breast implants are linked to an increased risk of this rare type of cancer.

Night Shifts Found to Increase Risk for Multiple Cancers in Female Nurses

A new international study found that night shift work significantly increases the risk of developing common cancers in women.

FDA Approves TRISENOX Injection for First Line Treatment of Acute Promyelocytic Leukemia

The U.S. Food and Drug Administration has approved the use of the intravenous drug TRISENOX (Teva Pharmaceutical Industries Ltd.) in combination with tretinoin for first line treatment of adult patients who have been newly-diagnosed with low-risk APL.

FDA Approves GammaPod for Breast Cancer Treatment

The U.S. Food and Drug Administration has approved a new breast cancer treatment machine that uses gamma rays to target tumors without harming healthy tissue.

NCCN Updates Clinical Practice Guidelines for Hodgkin Lymphoma

The National Comprehensive Cancer Network has issued updated guidelines for Hodgkin lymphoma, which focus on the management of HL using existing treatments and the need for long-term follow-up after treatment completion.

Targeted Therapy Halves Mortality Risk in Advanced Breast Cancer

An old treatment paradigm may be killing women.

Surgery Combined With EGFR-TKIs Can Extend NSCLC Survival

Which combination provides the best outcome for high-risk NSCLC? Here's the answer.

Roche Receives FDA Approval for Alecensa

Things are looking up for ALK-positive NSCLC patients, thanks to the recent FDA approval of Alecensa (alectinib), a highly selective ALK inhibitor that was shown to reduce the risk of disease worsening or death by 47% compared with crizotinib.

Eribulin Enormously Benefits Major Subset of Breast Cancer Patients

One group of breast cancer patients improves significantly following treatment with Eribulin.

NEJM Study Finds Osimertinib Exhibits 18.9 Months Progression-Free Survival vs. 10.2 Months With Standard Treatment for NSCLC Patients

The NEJM published results from a phase III trial showing that osimertinib exhibited longer progression-free survival and could be a new first-line treatment for patients with untreated EGFR-mutated NSCLC.

FDA Warns Patients That Thermogram is No Alternative to Mammogram

The U.S. Food and Drug Administration (FDA) has released a warning reminding patients that thermography should not replace mammography for breast cancer screening.

Adverse Events Caused 81% of Patients to Discontinue TKIs for CML, Study Finds

A new study found that adverse effects were the most common reason for patients with chronic myeloid leukemia to discontinue use of tyrosine kinase inhibitors.

New Combo Therapy Doubles Progression-Free Survival in Metastatic Breast Cancer Patients

A new study found that a combination of everolimus and fulvestrant doubled progression-free survival in these patients compared to fulvestrant alone.

NEW GUIDELINES: Safely Discontinue TKIs for Some CML Patients

Patients can take TKIs for the rest of their lives. But do they need to?

Liquid Biopsy Promising for Monitoring Post-Cystectomy Bladder Cancer

Measuring tumor-specific mutations in blood and urine samples may be useful for monitoring response to treatment and identifying early signs of metastases after radical cystectomy in patietns with advanced bladder cancer, according to researchers.